These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 22442719)

  • 61. Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines.
    Karanikolas BD; Figueiredo ML; Wu L
    Prostate; 2010 May; 70(6):675-88. PubMed ID: 20087897
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Elevated expression of prostate cancer-associated genes is linked to down-regulation of microRNAs.
    Erdmann K; Kaulke K; Thomae C; Huebner D; Sergon M; Froehner M; Wirth MP; Fuessel S
    BMC Cancer; 2014 Feb; 14():82. PubMed ID: 24517338
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2.
    Beke L; Nuytten M; Van Eynde A; Beullens M; Bollen M
    Oncogene; 2007 Jul; 26(31):4590-5. PubMed ID: 17237810
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer.
    Saramäki OR; Tammela TL; Martikainen PM; Vessella RL; Visakorpi T
    Genes Chromosomes Cancer; 2006 Jul; 45(7):639-45. PubMed ID: 16575874
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells.
    Orzan F; Pellegatta S; Poliani PL; Pisati F; Caldera V; Menghi F; Kapetis D; Marras C; Schiffer D; Finocchiaro G
    Neuropathol Appl Neurobiol; 2011 Jun; 37(4):381-94. PubMed ID: 20946108
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy.
    Gee JR; Saltzstein DR; Messing E; Kim K; Kolesar J; Huang W; Havighurst TC; Harris L; Wollmer BW; Jarrard D; House M; Parnes H; Bailey HH
    Eur J Cancer Prev; 2016 Jul; 25(4):312-20. PubMed ID: 26313229
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Collaboration of Kras and androgen receptor signaling stimulates EZH2 expression and tumor-propagating cells in prostate cancer.
    Cai H; Memarzadeh S; Stoyanova T; Beharry Z; Kraft AS; Witte ON
    Cancer Res; 2012 Sep; 72(18):4672-81. PubMed ID: 22805308
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results.
    van Gils MP; Hessels D; Hulsbergen-van de Kaa CA; Witjes JA; Jansen CF; Mulders PF; Rittenhouse HG; Schalken JA
    Prostate; 2008 Aug; 68(11):1215-22. PubMed ID: 18500693
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Targeting bone remodeling by isoflavone and 3,3'-diindolylmethane in the context of prostate cancer bone metastasis.
    Li Y; Kong D; Ahmad A; Bao B; Sarkar FH
    PLoS One; 2012; 7(3):e33011. PubMed ID: 22412975
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Downregulation of hsa_circ_0026123 suppresses ovarian cancer cell metastasis and proliferation through the miR‑124‑3p/EZH2 signaling pathway.
    Yang X; Wang J; Li H; Sun Y; Tong X
    Int J Mol Med; 2021 Feb; 47(2):668-676. PubMed ID: 33416105
    [TBL] [Abstract][Full Text] [Related]  

  • 71. EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin.
    Tong ZT; Cai MY; Wang XG; Kong LL; Mai SJ; Liu YH; Zhang HB; Liao YJ; Zheng F; Zhu W; Liu TH; Bian XW; Guan XY; Lin MC; Zeng MS; Zeng YX; Kung HF; Xie D
    Oncogene; 2012 Feb; 31(5):583-94. PubMed ID: 21685935
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Developmental and androgenic regulation of chromatin regulators EZH2 and ANCCA/ATAD2 in the prostate Via MLL histone methylase complex.
    Duan Z; Zou JX; Yang P; Wang Y; Borowsky AD; Gao AC; Chen HW
    Prostate; 2013 Apr; 73(5):455-66. PubMed ID: 23038103
    [TBL] [Abstract][Full Text] [Related]  

  • 73. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.
    Zhang JG; Guo JF; Liu DL; Liu Q; Wang JJ
    J Thorac Oncol; 2011 Apr; 6(4):671-8. PubMed ID: 21270667
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer.
    Kirk JS; Schaarschuch K; Dalimov Z; Lasorsa E; Ku S; Ramakrishnan S; Hu Q; Azabdaftari G; Wang J; Pili R; Ellis L
    Oncotarget; 2015 Feb; 6(5):3136-46. PubMed ID: 25605014
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Increased expression of EZH2, a polycomb group protein, in bladder carcinoma.
    Arisan S; Buyuktuncer ED; Palavan-Unsal N; Caşkurlu T; Cakir OO; Ergenekon E
    Urol Int; 2005; 75(3):252-7. PubMed ID: 16215315
    [TBL] [Abstract][Full Text] [Related]  

  • 76. MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth.
    Nadiminty N; Tummala R; Lou W; Zhu Y; Shi XB; Zou JX; Chen H; Zhang J; Chen X; Luo J; deVere White RW; Kung HJ; Evans CP; Gao AC
    PLoS One; 2012; 7(3):e32832. PubMed ID: 22479342
    [TBL] [Abstract][Full Text] [Related]  

  • 77. MicroRNA-144 suppresses tumorigenesis and tumor progression of astrocytoma by targeting EZH2.
    Lin L; Zheng Y; Tu Y; Wang Z; Liu H; Lu X; Xu L; Yuan J
    Hum Pathol; 2015 Jul; 46(7):971-80. PubMed ID: 25907866
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression.
    Bao B; Ali S; Banerjee S; Wang Z; Logna F; Azmi AS; Kong D; Ahmad A; Li Y; Padhye S; Sarkar FH
    Cancer Res; 2012 Jan; 72(1):335-45. PubMed ID: 22108826
    [TBL] [Abstract][Full Text] [Related]  

  • 79. EZH2 activates CHK1 signaling to promote ovarian cancer chemoresistance by maintaining the properties of cancer stem cells.
    Wen Y; Hou Y; Yi X; Sun S; Guo J; He X; Li T; Cai J; Wang Z
    Theranostics; 2021; 11(4):1795-1813. PubMed ID: 33408782
    [No Abstract]   [Full Text] [Related]  

  • 80. MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes.
    Liu C; Liu R; Zhang D; Deng Q; Liu B; Chao HP; Rycaj K; Takata Y; Lin K; Lu Y; Zhong Y; Krolewski J; Shen J; Tang DG
    Nat Commun; 2017 Jan; 8():14270. PubMed ID: 28112170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.